Trial Profile
Randomized Phase II Trial Evaluating the Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab as Perioperative Treatment in Patients With Resectable Liver Metastases From Wild Type KRAS/NRAS Colorectal Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Dec 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Panitumumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer; Liver metastases
- Focus Therapeutic Use
- Acronyms BOS2
- 24 Dec 2021 This study has been completed in Belgium,according to European Clinical Trials Database.
- 20 Jul 2020 This study has been completed in United Kingdom according to European Clinical Trials Database.
- 16 May 2019 This study has been completed in Netherlands.